MYL News and Press, Mylan N.V. From 11/06/20

Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...

Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...

Mylan (NASDAQ:MYL) is scheduled to announce Q3 earnings results on Friday, November 6th, before market open.The consensus EPS Estimate is $1.16 (-0.9% Y/Y) and the consensus Revenue Estimate is $3B (+1.4% Y/Y).Analyst expects adjusted gross margin of 53.1%.Over the last 2 years, MYL has ...

[[AES]], [[AMRX]], [[COTY]], [[CQP]], [[CVS]], [[CWT]], [[DISH]], [[DOC]], [[ELAN]], [[ENB]], [[EPZM]], [[ESNT]], [[GCP]], [[GOLF]], [[HMSY]], [[HRC]], [[HSY]], [[LNG]], [[MAR]], [[MBUU]], [[MD]], [[MGA]], [[MOG.A]], [[MYL]], [[PRIM]], [[SABR]], [[SSP]], [[TILE]], [[TU]], [[UFS]], [[VIAC]], [...

Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...

The merger of Pfizer 's (NYSE: PFE) generic drug business, Upjohn, with Mylan (NASDAQ: MYL) will be going through shortly, now that the companies have agreed to a consent order with the U.S. Federal Trade Commission. The companies didn't give any details about what they had ...

Pfizer Announces Record Date for the Proposed Transaction Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Federal Trade Commission (the “FTC”) accepted a proposed consent order, which concludes the FTC’s review of t...

The U.S. Federal Trade Commission ((FTC)) announces that Pfizer ([[PFE]] -0.7%) and Mylan N.V. ([[MYL]] +1.1%) have agreed to agency conditions for approving the proposed combination of Pfizer's Upjohn unit and Mylan which will do business as Viatris.Citing harm to competition in 10 generic d...

Pfizer is trading at an inexpensive valuation and offers a reliable dividend with an above-average yield. The stock has some upside potential over the coming years, and combined with the dividend, total returns could be very solid. In a best-case scenario, Pfizer could be the lead...

The coronavirus vaccines are coming -- or at least the odds are looking better every day that they are. Investors who want to potentially benefit from the launches of coronavirus vaccines have plenty of options from which to choose. However, the number of low-risk leaders in the race are few. H...